RxDoctor Payments Data

Patrick Albergo, MD

Ophthalmology · West Hartford, CTNPI 1407878754

Payments from drug & device makers

$1,876in general payments, 2019–2025

Across 75 payments — averaging $25.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$569
  • Carl Zeiss Meditec USA, Inc.$480
  • Amgen$164
  • Oyster Point Pharma, Inc.$156
  • Bausch & Lomb Americas Inc.$146
  • Alcon$76
  • plus $285 from 8 others

What the payments were for

  • Food & beverage$1,39574%
  • Other$48026%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,876 in reported general payments places this provider in the 65th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$140,787
Medicare patients
515
Services billed
1,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost110$69,697
RhopressaNetarsudil Mesylate95$63,766
RestasisCyclosporine40$61,073
CombiganBrimonidine Tartrate/Timolol43$24,993
RocklatanNetarsudil Mesylat/Latanoprost28$24,644
Timolol Maleate372$21,947
Cyclosporine26$13,339
TyrvayaVarenicline Tartrate13$13,326
VyzultaLatanoprostene Bunod18$11,932
MieboPerfluorohexyloctane/Pf12$11,570
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$8,471
Alphagan PBrimonidine Tartrate15$7,772
Brimonidine Tartrate160$7,191
Latanoprost498$6,421
Prednisolone Acetate237$6,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$569$163,535208 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$28$88,410123 claims
Bausch & Lomb Americas Inc.Vyzulta, Miebo$146$23,50330 claims
Oyster Point Pharma, Inc.Tyrvaya$156$13,32613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in West Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →